great post! it is now about execution. Cannepil needs to drive the revenue from the pharma side for the next 18 months. Hopefully there are a series of clinical trials that happen like cogicann which will increase the revenue from there. Botanic side should sell raw materials and hopefully the derma deal is all kosher and we get a regular revenue from there.
Let's hope they can get enough revenue to break even from cannepil and the botany side ….
great post! it is now about execution. Cannepil needs to drive...
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.015(3.80%) |
Mkt cap ! $17.20M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 39.5¢ | 38.0¢ | $2.163K | 5.582K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4763 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 52 | 1 |
View Market Depth
| Last trade - 15.42pm 08/05/2024 (20 minute delay) ? |
| RGT (ASX) Chart |